{'fraction_non_alphanumeric': 0.013966480446927373, 'fraction_numerical': 0.0, 'mean_word_length': 5.961165048543689, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anticoagulation for venous thromboembolism

PREVIEW Treatment of venous thromboembolism is undergoing rapid change, particularly with the advent of low- molecular-weight heparins. But how does the performance of these new agents stack up against standard treatment with unfractionated heparin? And what are the issues involved in thrombolytic therapy for deep venous thrombosis and pulmonary embolism? Drs Yacovella and Alter make sense of the current data and controversies regarding anticoagulation and thrombolytic therapy. They also discuss consensus opinion about the available therapeutic options and, when consensus is lacking, offer their own recommendations on appropriate choices and duration of treatment.